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Background: Epstein-Barr virus (EBV) is an etiological cause of many human lymphocytic and epithelial
malignancies. EBV expresses different genes that are associated with three latency types. To date, as many as
44 EBV-encoded miRNA species have been found, but their comprehensive profiles in the three types of latent
infection that are associated with various types of tumors are not well documented.
Methods: In the present study, we utilized poly (A)-tailed quantitative real-time RT-PCR in combination with
microarray analysis to measure the relative abundances of viral miRNA species in a subset of representative
lymphoid and epithelial tumor cells with various EBV latency types.
Results: Our findings showed that the miR-BHRF1 and miR-BART families were expressed differentially in a tissue-
and latency type-dependent manner. Specifically, in nasopharyngeal carcinoma (NPC) tissues and the EBV-positive
cell line C666-1, the miR-BART family accounted for more than 10% of all detected miRNAs, suggesting that these
miRNAs have important roles in maintaining latent EBV infections and in driving NPC tumorigenesis. In addition,
EBV miRNA-based clustering analysis clearly distinguished between the three distinct EBV latency types, and our
results suggested that a switch from type I to type III latency might occur in the Daudi BL cell line.
Conclusions: Our data provide a comprehensive profiling of the EBV miRNA transcriptome that is associated with
specific tumor cells in the three types of latent EBV infection states. EBV miRNA species represent a cluster of
non-encoding latency biomarkers that are differentially expressed in tumor cells and may help to distinguish
between the different latency types.
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Increasing evidence suggests that EBV is an oncogenic hu-
man virus that causes many malignancies [1-3]. The EBV-
encoded LMP1 gene is considered a viral oncogene that
leads to the development of several tumor types [4,5]. Viral
microRNA species have been found in EBV-infected cells
[6] and recent studies indicate that 44 EBV miRNA species
are involved in the establishment of viral latency and
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reproduction in any medium, provided the orEBV miRNA transcriptomes in tumor cells in the three
types of latency states has not been performed. In this
study, we investigated the comprehensive expression pat-
terns of EBV miRNA species in cells with different types of
latency and emphasized the viral miRNA patterns in NPC
tissues and cells in the EBV latency II state.
MiRNAs play physiological and pathophysiologic roles in
cell proliferation, differentiation and apoptosis by regu-
lating protein expression in a post-transcriptional manner.
Furthermore, miRNA regulation is an innate defense me-
chanism against viruses in host cells. Over the course of
evolution, a subset of viruses, including the herpesviruses,
has obtained the ability to hijack this antiviral mechanism
of host cells to help maintain a persistent infection [13-16].d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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latent viral infections, and this latency is controlled by vari-
ous viral genetic and epigenetic regulatory mechanisms
[15,16]. Virus-encoded miRNAs play significant roles in
maintaining persistent EBV infections by down-regulating
the expression of viral immediate-early genes [7,17-19] and
promoting the tumorigenesis of host cells. In addition,
these viral miRNAs help the virus evade host immune de-
fenses [9,11,20,21] by regulating host gene expression at
the post-transcriptional level.
The classification of EBV latency is an academic and
clinical issue because latent infections of different types are
associated with different tumors [15]. The traditional clas-
sification system is based on only a few molecular markers
of EBV latency, including EBERs, EBNA1-6, LMP1, LMP2
and BARTs [2,22-25], and typing of EBV latency types has
limitations. Since EBV was first found to encode viral miR-
NAs in 2004 [6], 44 mature, EBV-encoded miRNA species
have been registered in the Sanger miRBase library (Re-
lease 16.0). EBV miRNA species are produced from a large
intron in BARTs (BamHI A rightward transcripts) prior to
splicing [26,27]. Therefore, these novel, abundant markers
of viral latency may help in obtaining further insight into
EBV and may be useful as novel, biomarkers for identifying
latency types [12,28].
MiRNAs are a class of difficult-to-detect RNA strands
that are 19–23 nt in length. These RNAs can currently be
analyzed by high-throughput microarray analysis [29,30],
SOLEXA sequencing [31], Northern blotting [32] and
quantitative real-time RT-PCR [33]. Given the higher sen-
sitivity and specificity of qPCR [34], in this study, we
mainly used a poly(A)-tailed, qRT-PCR technique in com-
bination with a microarray assay to analyze the expression
patterns of the EBV miRNA transcriptomes that are asso-
ciated with specific latency types in various tumor cells.
Additionally, we primarily evaluated a type I to III tran-
sition based on clustering analysis of the EBV miRNA
species.
Results
Quantitative analysis of viral-coding transcripts in EBV-
infected cell lines and NPC tissues
The previous identification of the EBV latency types was
mainly based on viral EBERs, nuclear antigens, LMP1,
LMP2 and the Bam H1 rightward transcripts [2,22-25].
EBNA1 is expressed under the alternative promoters Wp,
Cp and Qp in a latency type-specific manner [22,24,35],
and LMP1 exhibits differential abundance when compared
to the various latency types [1], suggesting that the activ-
ities of the three latency promoters that control EBNA1
expression and LMP1 abundance can characterize the
three latency types. The essential latency characteristics de-
scribed above are partially illustrated in Figure 1. In the
present study, we measured the activities of the Cp/Qp/Wp promoters and the expression level of LMP1 to
characterize the different types of latent EBV infections.
We examined the expression levels of the traditional la-
tency biomarkers by quantitative real-time RT-PCR in a
subset of typical tumor cell lines and NPC tissues with
different EBV latency types. During latency I (Daudi and
Akata(+) cells) [36,37] and latency II (C666-1 and T4-T7
cells) [38], Qp exhibited a much higher activity than in la-
tency III (B95-8, Raji and Namalwa cells). When compared
with high-stringent latency I (Akata(+) cells), latency II
(C666-1 and T4-7 cells) and latency III (B95-8 and Raji
cells) were associated with slightly higher expression levels
of LMP1. During low-stringent latency I (Daudi), the ex-
pression of the latency II/III biomarker LMP1 appeared to
be elevated. Interestingly, viral latency biomarkers were
nearly undetected by both methods in Namalwa cells, im-
plying that the majority of the EBV episomes might be lost
during culture (Figure 2).
The comprehensive expression patterns of EBV miRNA
species in three types of latency states
EBV miRNA species are expressed as two independent
transcripts, BHRF1 and BART. The miR-BHRF1 family is
located within the introns of BHRF1 (Bam HI fragment H
rightward open reading frame 1) [10,39,40], whereas the
miR-BART family is located in the intronic regions of the
BART and form two separate clusters (cluster I and cluster
II) [26,27]. The prototypic EBV strain that was derived
from the B95-8 cell line has a 12-kb deletion that spans the
two BART clusters from miR-BART-5 to 14 [41,42]. A de-
tailed overview of the genomic locations of the EBV
miRNA genes is presented in Figure 1.
In our investigation, we mainly used real-time RT-
PCR to gain insight into the comparable profiles of the
EBV miRNA transcriptomes of the three latency types.
To confirm the specificity of the PCR products and ver-
ify the reliability of this poly(A)-tailed, real-time qPCR
method, we randomly sequenced three qPCR products,
submitted them to AT cloning procedures, and the
results of DNA sequencing are shown in Figure 3C.
Following qPCR analysis, we further evaluated the ex-
pression levels of EBV miRNAs using a microarray
assay, and the scanning images are shown in Figure 3D.
In addition, correlation analysis showed statistically sig-
nificant correlations between the two methods for the
latency I (Akata(+) cells; Pearson’s correlation coeffi-
cient = 0.51, p = 0.0004), latency II (C666-1 cells; Pearson’s
correlation coefficient = 0.73, p < 0.0001) and latency III
profiles (Raji cells; Pearson’s correlation coefficient = 0.47,
p = 0.0024) (Figure 3E).
The quantitative analysis of the EBV miRNAs in each la-
tency type yielded a comprehensive expression pattern of
the EBV miRNA species (Figure 3A). Generally, the BHRF1
family exhibited a nearly 100-fold higher abundance in
EBERs Cp Wp EBNA-LP EBNA2 Qp EBNA3A/3B/3C EBNA1 LMP2A LMP1
(I~III) (III) (III) (I, II)                             Bam A fr.  (II, III)  (II, III)
BARTs Promoter
BHRF1 Promoter (I~III+Lytic)
 BHRF1   BFLF2   BILF2   B95.8 deletion   BILF1  BALF5
miR-BHRF1-1 miR-BHRF1-2 miR-BHRF1-3 miR-BART 3,4,1,15   miR-BART2
LF3 LF2 LF1
miR-BART 5,16,17,6 miR-BART21,18,7~9  miR-BART 19,20,13,14
miR-BART 22,10~12
Figure 1 Genomic locations of all viral miRNA species. The top panel shows the position of latent genes and promoters (pennants). The
middle panel shows the position of the EBV miRNAs, including the miR-BHRF1 and miR-BART families. The promoters of the BHRF1 and
BART families are marked with pennants, and the EBV miRNA species whose genes are located within the deletion region in the prototype,
B95-8-derived strain are shown in the lower panel. The locations of EBV miRNA genes are listed in genomic order from miRBase.
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and Daudi cells), whereas the expression of the BHRF1
family was nearly absent in latency II (C666-1 cells),
suggesting that the expression of the BHRF1 family is
latency-III dependent. In addition, the BART family was
differentially expressed in cells with the three latency types
(Akata(+), Daudi, C666-1, Raji and B95-8 cells), with the
exception of Namalwa cells, suggesting that the BARTFigure 2 Characteristic expression patterns of EBV latency biomarker
derived from promoters Q (Qp), C (Cp), and W (Wp) and the expression of
three different EBV latency types by quantitative RT-PCR. Daudi and Akata(+
latency. T4, T5, T6 and T7 are pathologically confirmed, clinical NPC (nasop
C666-1 cell line is an epithelial NPC cell line that consistently harbors EBV. T
B95-8 cell line is a macaque lymphoblastoid cell line (LCL) harboring a prot
negative controls, each qPCR reaction was run in triplicate, and the relative
(2-ΔΔCt) with normalization to GAPDH.family plays differential roles in tumors with the three types
of latency. Notably, the average expression level of the
BART family in the epithelial tumor cell line C666-1, which
is a latency II cell line, was the highest of all latency types,
indicating that the BART family may contribute more to
NPC tumorigenesis. In contrast, the expression level of the
BHRF1 family was significantly higher than that of the
BART family in the lymphoid tumor cell line Raji, which iss for viral-coding genes. The levels of EBNA1 transcripts that were
LMP1 (latent membrane protein 1) were detected in cells having the
) cells are EBV-positive BL (Burkitt’s lymphoma) cells with type I
haryngeal carcinoma) specimens with EBV type II latency, and the
he Raji and Namalwa cell lines are EBV latency III BL cell lines, and the
otype EBV strain. Akata(−), CNE2 and Ramos cells were used as EBV-
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Figure 3 (See legend on next page.)
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Figure 3 Comprehensive and quantitative profiling of the EBV miRNA transcriptome in cells with the three latency types. (A) The
comparable results from poly(A)-tailed, real-time RT-PCR analysis of the EBV-encoded miRNA transcriptome in the cell lines with latency I, II and III.
The respective positions of the four clusters of EBV miRNAs (miR-BHRF1, miR-BART clusters I/II, miR-BART2 and the B95-8 deletion region) are
marked below, and the numbers under the lines indicate the EBV genomic locations (nt). (B) Differential amplification curves of EBV miRNA
species between epithelial and lymphoid tumor cells. The amplification curves of EBV miRNAs in C666-1 and Raji cells are separated distinctly into
two parts: in epithelial C666-1 cells, the EBV BART family generally had lower Ct values than the BHRF1 family (left); and the opposite results were
observed for the lymphoid Raji cells (right). (C) Verification of qPCR product specificity via DNA sequencing based on AT cloning. Representative
DNA sequence results are shown for three, randomly selected qPCR products, the BHRF1 family member BHRF1-1 and two BART family members,
Bart5 and Bart15. (D) An overview image from the microarray analysis of human miRNAs and EBV miRNAs in C666-1 cells (left). The right panel
displays a subset of the hybridization signals for EBV miRNAs in the indicated region of the chips for tumor cell lines with various EBV latency
types and including the EBV-negative cell line CNE2. (E) Correlation between the microarray read counts and the expression levels that were
determined by real-time PCR of EBV miRNAs that were detected in cells with various latency types. The microarray and real-time PCR results were
log2-transformed and analyzed using Person’s correlation analysis. Pearson’s correlation coefficients and p-values are shown in the inserts.
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families are somewhat tissue-specific (Figure 3B). Inte-
restingly, the BART and BHRF1 families were nearly un-
detectable in Namalwa cells, suggesting that EBV episomes
might have been lost by these host cells in vitro.
Although a large difference between the expression
levels of the BHRF1 and BART families was found in the
same cell line, the difference between BART clusters I
and II was relatively small in Akata(+), Daudi, C666-1
and Raji cells. This result suggests that BART clusters I
and II are spliced from a common transcript, as was re-
ported previously. Notably, 31 members of the EBV
miRNA species that were barely detectable by qPCR are
located in the 12-kb deletion in the prototypic B95-8-
derived EBV strain that spans nts 139724–151554 of the
EBV genome (GenBank accession number AJ507799.2).
A detailed schematic of the deletion region in the B95-
8-derived strain is shown in Figure 1. A subset of B95-8
cells can produce infectious EBV virions that are re-
leased into the medium during culture, which is a sign
that the EBV life cycle has switched from latency to lysis.
This switch might be related to the miRNAs that are
encoded in the deleted region. That is, the miRNAs
in the 12-kb deletion region could be involved in main-
taining EBV latency. As for Akata(+) cells, which are
high-stringent latency I cells, the abundance of the
BHRF1 family was 10- to 100-fold lower than that of
the BART family and was similar to its abundance in the
high-stringent latency II cell line C666-1 (Figure 3A).
Recent studies on the EBV methylome have found that
hypermethylation of the promoter of the BHRF1 gene
leads to its low expression in Akata cells, which is con-
sistent with our present results [43].
EBV miRNA transcriptome in primary NPC tissues and
C666-1 cells with type II latency
NPC tissues and the NPC cell line C666-1, which was the
only cell line that persistently carried EBV, exhibited high-
stringent, type II EBV latency [2,25,38,44]. In this study, we
explored the EBV miRNA expression status ofpathologically confirmed, NPC biopsy specimens, and our
results indicated that the BHRF1 family was expressed at a
low level, whereas the BART family showed much higher
abundance in NPC samples and C666-1 cells (Figure 4A).
The Pearson and Spearman correlation analyses of BART
miRNA expression of these NPC samples and the C666-1
cell line showed great similarity, suggesting that the mech-
anism by which the EBV BART family regulates latency is
the same in different NPC tumors (Figure 4B). The average
expression level of the BART family in the NPC tissue sam-
ples also showed a strong correlation with its expression
level in the NPC cell line C666-1 (R = 0.89, p < 0.0001)
(Figure 4B). These results show that the EBV miRNA ex-
pression level in C666-1 cells is consistent with its pattern
in NPC tissues, indicating that the C666-1 cell line is an
ideal model for investigating the relationship between EBV
and NPC. In addition, results of previous investigations on
the pattern of EBV miRNA expression in NPC tissues
using a stem-loop, RT primer-based qPCR assay are gener-
ally in agreement with our present results. We also evalu-
ated the ratio of viral miRNAs to human miRNAs using
the microarray data, and we found that the ratio was
greater than 10% (Figure 4C). This result was also consist-
ent with those of previous studies [31,45,46] and further in-
dicates that EBV miRNAs might play important roles in
NPC tumorigenesis.Evaluation of a possible transition from type I to III
latency in Daudi cells that is dependent on viral miRNAs
The viral miRNAs that are differentially expressed in
different types of EBV-infected cells are expected to
help distinguish between the different latency types. In
this study, we performed unsupervised, clustering ana-
lysis based on the qPCR dataset to examine the two
types of indicators that are used to type latency. Inter-
estingly, the human Burkitt’s lymphoma cell line Daudi
[36,37], which was classified into the latency I group
based on latency markers (Cp, Wp, Qp and LMP1), was



















Figure 4 The pattern of the EBV miRNA transcriptome in NPC cells and tissues in the latency II state. (A) RT-PCR analysis of the EBV
microRNA transcriptome in the persistently EBV-positive cell line C666-1 and three NPC tissue samples. U6 was used as an internal control. The
whole EBV miRNAome is grouped into four clusters based on genomic location in sequential order. (B) Spearman and Pearson correlations
between the C666-1 cells and the three NPC tissue samples (left). The expression levels of the EBV miRNAs were quantified by real-time RT-PCR.
The data shown in the lower left portion are Pearson’s correlation coefficients, and the values shown in the upper right portion are Spearman’s
correlation coefficients. To calculate the correlations, the real-time PCR results for the NPC tissues and C666-1 cells were log2-transformed and
analyzed using Person’s correlation analysis. Pearson’s correlation coefficients and p-values are shown. The average expression level of each EBV
miRNA species in the three NPC tissues is plotted on the x-axis (right). (C) Proportions of the respective human and EBV miRNA species that were
detectable in C666-1 cells (left) and two NPC samples (middle and right) based on the microarray analysis. The EBV-encoded miRNAs accounted
for more than 10% of the entire human miRNA library in the NPC samples in vivo and in vitro.
Yang et al. Virology Journal 2013, 10:314 Page 6 of 13
http://www.virologyj.com/content/10/1/314
Yang et al. Virology Journal 2013, 10:314 Page 7 of 13
http://www.virologyj.com/content/10/1/314miRNA latency markers (Figure 5A). Additionally, clus-
tering analyses based on non-encoding miRNA species
and their encoding latent genes categorized Daudi cells
into the latency III group (Figure 5A). To evaluate the
accuracy of the latter two clustering results, we per-
formed phenotypic and genotypic investigations. Based
on phenotypic characteristics (shown in Figure 5B), we
observed that, in culture, Daudi cells grew as macro-
scopic clumps that were similar to those of the typical
latency III cell line B95-8, whereas the high-stringent,
latency I Akata(+) cells grew as a single-cell suspension,
which is a typical characteristic of BL cells in latency I.
The same phenomenon regarding the Daudi cell line
was also observed in a recent study [12], suggesting that
the EBV latency type might have switched from type I
to III during the course of long-term culturing of Daudi
cells. Additionally, we examined a latency type-specific
change at the viral gene level when comparing high-
stringent latency I Akata(+) cells, which have no LMP1
expression and lower Wp activity, to Daudi cells, which
began to express the type III-associated marker LMP1
and had elevated Wp activity despite the persistence
of higher Qp activity (Figure 5C). In addition to the
changes in the encoding latency biomarkers, changes in
the expression levels of viral non-coding biomarkers, in-
cluding the BHRF1 and BART families, occurred in
Daudi cells. In the representative type I cell line Akata(+),
the average expression level of the BART family was
much higher than that of the BHRF1 family, whereas
the BHRF1 family had a slightly higher abundance than
the BART family in Daudi cells, indicating that a tran-
sition from type I to type III latency had possibly oc-
curred in the tested Daudi cells (Figure 5C). It seems
that the limited number of traditional viral latency bio-
markers is inadequate to clearly distinguish between the
differential EBV latency types, whereas a cluster of dif-
ferentially expressed miRNA species maybe reinforce
these demands.
Characterization of latent EBV coding and noncoding
transcripts in cells and NPC tissues
The different EBV latency types are closely related to vari-
ous malignancies, and, consequently, the correct identifi-
cation of latency types is critical for understanding the
virus’s contribution to carcinogenesis. EBV-encoded miR-
NAs were first found in 2004 [6], and, currently, as many
as 44 EBV miRNA species have been found and registered
in the Sanger miRBase. In this study, which is based on
our comprehensive and comparable investigation of most
EBV latency biomarkers, including coding and noncoding
transcripts of the three latency types, we provide add-
itional information on the in-depth characterization of
EBV latent infections, as summarized in Table 1. In light
of our analysis of viral latency biomarkers, these viral,non-encoding miRNA species should be considered when
classifying the latency types of EBV-infected tumor cells.Discussion
In light of the roles of human miRNAs under physio-
logical and pathological conditions, especially in the
process of carcinogenesis [47], the discovery of EBV-
encoded miRNAs is an important event and a milestone
in molecular virology that provided us with new insight
into the relationship between a virus and its host cell.
Earlier investigations showed that, in addition to EBV,
other viruses such as HSV1/2 [19,48], HCMV [18], SV40
[21], KSHV [32] and even HIV [49] encode their own
miRNAs, suggesting that, during long-term evolution,
some viruses have hijacked this innate antivirus mechan-
ism to serve themselves or to manipulate human cellular
miRNAs to target viral genes [50]. Theoretically, the
ability of a subset of viruses to encode their own miR-
NAs is an adaptive response to environmental stress be-
cause of the low immunogenic risk to the virus that is
posed by those noncoding miRNAs [16,51].
Epstein-Barr virus infects over 90 percent of adults
worldwide, and EBV infections are strongly associated
with multiple human diseases, especially some cancers.
In tumor cells, EBV genomes exist as episomes in a state
of latency that does not produce lytic viral particles that
can be detected by the host immune system. The EBV
genome encodes approximately 90 genes but only ex-
presses a few genes, such as EBERs, EBNA1-6, LMP1,
LMP2 and BARTs [25], in latent stages, and these genes
serve as markers for classical latency typing [23-25].
Based on the differential expression patterns of these
viral genes, latent infections are divided into three types.
In addition, tumors have different latency types, and the
latency type can change during in vivo and in vitro cul-
ture [12,52]. Since the identification of EBV-encoded
miRNAs in 2004 [6], researchers have increasingly fo-
cused their attention on investigating the relationships
between viral miRNAs and the establishment of EBV la-
tency and host carcinogenesis.
In this study, we analyzed the comprehensive expres-
sion patterns of EBV miRNA species using quantitative
real-time PCR and microarray assays in representative
tumor cell lines with the three latency types. The cell
lines included the type I latency cell lines Akata(+) and
Daudi, the type II latency cell line C666-1 and the type
III latency cell lines Namalwa, Raji and B95-8, and we
analyzed several NPC tissues. In addition, we explored
the profile of the EBV miRNA transcriptome in-depth.
Generally, the expression of the BHRF1 miRNA family is
dependent on the type of viral latency and the cell’s
histological origin, whereas the BART miRNA family is
expressed differentially in cells during all forms of
AB
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Figure 5 (See legend on next page.)
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Figure 5 Clustering analysis of the EBV miRNA transcriptome helps to identify a latency switch. (A) Clustering analysis of the three
latency types based on traditional EBV latency biomarkers (the EBNA1 promoters Cp, Wp, and Qp and LMP1) indicated that Daudi cells belonged
to the EBV latency I group (upper left). However, unsupervised clustering analysis based on all of the EBV miRNA species alone (lower left) and in
combination with classical latency biomarkers (right) suggested that Daudi cells might have undergone a transition from latency I to III. The three
heat maps above were constructed based on normalized qPCR data. (B) Phenotypic observation of the Daudi cells in culture. Bright-field
photomicrograph of three BL cell lines: B95-8 (left), Akata(+) (middle) and Daudi (right). The Daudi cells grew as macroscopic clumps, as was
observed for the LCL B95-8 cells (the latency III control), whereas Akata(+) cells (latency I control) grew as a single-cell suspension. (C) Genotypic
evaluation of the latency transition in Daudi cells. In contrast to Akata(+) cells, which exhibit latency I, Daudi cells had slightly higher levels of
EBNA1 Wp activity and LMP1 expression (left). In addition, the average expression level of the BHRF1 family was slightly higher than that of the
BART family in Daudi cells, which was in contrast to their patterns in Akata(+) cells (right).
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http://www.virologyj.com/content/10/1/314latency. Moreover, qPCR analysis indicated a difference
of nearly 100-fold between all tested cell lines, and the
expression of individual BART miRNA species within
one cell line could differ by 50-fold or more, although
those miRNAs were transcribed together as a single, pri-
mary transcript [27]. In contrast, the BART family was
expressed constantly at a high level without a significant
difference between its expression in EBV-positive NPC
tissues and the C666-1 cell line (latency II), suggesting
that the BART family is involved in maintaining EBV la-
tency and promoting NPC tumorigenesis. In fact, recent
research has demonstrated that the BART family plays
important roles in the establishment of EBV latency and
NPC initiation and development. Noticeably, ebv-miR-
bart6-5p can target the human dicer gene to control the
latency switch from type I/II to type III [52]. Briefly, our
results and emerging evidence indicate that EBV-
encoded miRNA species have a functional role in target









I Akata(+)(BL) - Low
I/III Daudi(BL) + Low
II C666-1 + None
NPC tissues +







Note: The abundance of all EBV latent coding and noncoding transcripts in the tabl
procedures respectively (see Materials and methods).
The abbreviation in the bracket indicates the tumor from which the cell lines were
BL: Burkitt’s lymphoma; LCL: Lymphoblastoid cell line.
-, negative; +/-,+,++ ,+++ indicate the level of EBV latent transcripts in an increasingNPC, which is prevalent in southern China, is a typical
model of type II EBV latency, in which only three
protein-coding genes are expressed: EBNA1, LMP1 and
LMP2A. Our results indicate that the noncoding BART
family was expressed highly and accounted for more
than 10% of all known human miRNAs, suggesting that,
like the viral oncogene LMP1, these abundant noncod-
ing miRNA species are likely involved in NPC pathogen-
esis. As in other viruses, the use of miRNAs is one of
the strategies used by the virus to evade host-immune
defenses because noncoding miRNAs, which have no
immunogenicity, cannot trigger the body’s immune re-
sponse. Therefore, the production of miRNAs is a rela-
tively low-risk and efficient regulatory mechanism for
maintaining a persistent infection and stability of its
genome [53]. In addition, we found that the EBV
miRNA transcriptome was somewhat stable in the NPC
tissues and the type II latency cell line C666-1, which
further suggested that the EBV BART family plays keyripts in cells and NPC tissues tested
RNA Non-coding miRNAs
romoter Activity BHRF1 family BART family
Wp Qp
Low High + ++
Medium High ++ +
Low High + +++
Medium Low + +/-
Low None +/- -
High Medium ++ +
- - - -
- - - -
- - - -
e above was determined through two different quantitative real time RT-PCR
established with the exception to LCL. NPC: Nasopharyngeal carcinoma;
order.
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results also imply that the NPC cell line C666-1 is an ap-
propriate cellular model to examine the EBV infection
status in vivo and is an ideal cell line for exploring the
relationship between EBV and NPC [38].
It is generally agreed that Burkitt’s lymphoma exhibits
EBV type I latency in vivo and that NPC exhibits type II
latency [44]. Latency I and II are low-risk types because
fewer immunogenic viral proteins are expressed during
those times than during high-risk latency III [52]. EBV-
positive cells cultured in vitro are not under surveillance
by the immune system of the host; therefore, these cells
experience little or no immune pressure, which may re-
sult in the loss of the virus or a change in its latency
type. This could explain why EBV is missing from nearly
all NPC cell lines, with the exception of the C666-1 cell
line. Similarly, lymphoma cells in long-term culture oc-
casionally lose EBV episomes, as was observed in the
Namalwa BL cell line in this study, where the BHRF1
and BART families were expressed at very low levels
(Figure 3A and D). Moreover, EBV can spontaneously
switch latency types in some lymphoma cells in vitro,
and the most common switch is a type I-to-type III tran-
sition [12]. However, certain subtle latency transitions
are difficult to detect and identify due to the absence of
more specific and sensitive latency biomarkers. Because
EBV miRNA species are a cluster of novel latency
markers consisting of 44 members, including the BHRF1
family and the BART family, that are differentially
expressed in host cells, we profiled the patterns of the
EBV miRNA transcriptome in tumor cells with the three
different latency types, and we expected that clustering
analysis would distinguish between the three latency
types. We primarily observed a latency switch from type
I to type III in the Daudi BL cell line, which was previ-
ously regarded to be a cell line in the latency I state, dur-
ing the clustering analysis, and we further investigated
this switch by phenotypic and genotypic analyses. It
seems that these numerous, noncoding viral miRNA
species might be informative and valuable for determin-
ing latency type.
Conclusions
Viral noncoding miRNAs seem to be preferential regula-
tory tools that are extensively utilized by EBV due to their
low immunogenicity. Thus, EBV is a good model for
studying the role of viral miRNA regulation in the main-
tenance of latency. Our results suggest that these differen-
tially expressed viral miRNAs are molecular biomarkers of
latent infection and may be useful in identifying latency
types. In particular, the BART family contributes greatly to
epithelial tumors and to some lymphomas, whereas the
BHRF1 family is primarily responsible for a subset of
lymphocyte tumors. Our data provide fine profiles of theEBV miRNA transcriptomes that are associated with the
three EBV latency types and suggest that different viral
miRNA species are involved in various host-cell carcino-
genesis processes.
Materials and methods
Cell culture and tissues
The cell lines and tissues used in this study are listed in
Table 2. The Daudi, Raji and B95-8 cell lines were obtained
from the American Type Culture Collection (www.atcc.
org). The Namalwa, Akata, Ramos and CNE2 cell lines
were kindly provided by Prof. Musheng Zeng (Cancer
Center, Sun Yat-Sen University), and the C666-1 cell line
was a gift from The Chinese University of Hong Kong
(CUHK, Hong Kong SAR, China) [38]. All of the cells were
maintained in RPMI media with 10% fetal bovine serum
(Gibco, USA) and 1% penicillin-streptomycin and were in-
cubated in 5% CO2 at 37°C in a humidified atmosphere.
The primary NPC tissues used in this research were biop-
sies obtained from the Cancer Center at Sun Yat-Sen Uni-
versity (Guangzhou, China) prior to any treatments and
were pathologically confirmed as nondifferentiated non-
keratinizing carcinomas (UNKC, WHO type III). This pro-
ject was performed in agreement with the clinical ethics
guidelines, and all clinical samples were collected and ana-
lyzed with prior written, informed consent from the pa-
tients. This project was approved by the Research Ethics
Committee of the Sun Yat-Sen University Cancer Center.
Small RNA-enriched total RNA isolation
Total RNA containing low-molecular-weight RNAs was
prepared using the TRIzol method with minor modifica-
tions. Briefly, to extract more small RNAs, following the
first precipitation, the resulting upper aqueous phase
was mixed with 0.5 ml pre-cooled, isopropyl alcohol per
1 ml of TRIzol Reagent, and this mixture was then
placed at −20°C for 45 min and then spun at 12,000 × g
at 4°C for 45 min. The pellets were washed in 75% etha-
nol and then allowed to air dry for 5 min. The RNA pel-
lets were resuspended in nuclease-free water, quantified
by UV spectrophotometry (Nanodrop, Thermo, USA),
aliquoted and stored at −80°C.
Quantitative RT-PCR analysis of viral-coding gene
expression
The three EBNA1 promoter activity patterns (known as
Wp, Cp and Qp) and LMP1 expression were analyzed
by quantitative RT-PCR assays using an ABI7900HT
Fast Real-Time PCR System (Applied Biosystems, USA).
The housekeeping gene GAPDH was used as an internal
control to verify the RNA quality and loading accuracy.
Reverse transcription of 2 μg of total RNA was per-
formed using M-MLV reverse transcriptase (Promega,
USA) according to the manufacturer’s guidelines. The
Table 2 Histopathological and EBV infectious characterization of all cell lines and cancer tissues used in this study
Cell line/Tissue Pathology/Cell type EBV status Latency type Reference
CNE2 NPC/epithelial - -
Ramos BL/B lymphocytic - - [55]
Akata(-) BL/B lymphocytic - - [56]
Daudi BL/B lymphocytic + I [36]
Akata(+) BL/B lymphocytic + I [56]
C666-1 NPC/epithelial + II [38]
Raji BL/B lymphocytic + III [57]
Namalwa BL/B lymphocytic + III [58]
B95-8 LCL/B lymphoblastoid + III [59]
T1 NPC(UNKC)/epithelial + II
T2 NPC(UNKC)/epithelial + II
T3 NPC(UNKC)/epithelial + II
T4 NPC(UNKC)/epithelial + II
T5 NPC(UNKC)/epithelial + II
T6 NPC(UNKC)/epithelial + II
T7 NPC(UNKC)/epithelial + II
NPC: Nasopharyngeal carcinoma.
UNKC: Undifferentiated non-keratinizing carcinoma.
BL: Burkitt lymphoma.
LCL: Lymphoblastoid cell line.
T1-7: pathologically confirmed NPC biopsy specimens.
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Ramos were used as negative controls for type I, II and
III latency, respectively. In the qPCR assay, each reaction
was run in triplicate tubes in the presence of SYBR
green I, and the raw Ct values were normalized to that
of the housekeeping gene GAPDH. The PCR primer se-
quences for all analyzed genes are listed in Additional
file 1: Table S1. The DNA oligonucleotides that were
used as PCR primers and the chip probes in the study
were synthesized and HPLC-purified by Invitrogen Inc.
(Guangzhou, China).
Poly (A)-tailed, quantitative real-time RT-PCR analysis of
the EBV miRNA species
The All-in-One miRNA qRT-PCR Detection Kit (Gene-
Copoeia, USA) was used to determine the miRNA levels
in the samples. Briefly, poly(A) polymerase was used to
add poly(A) tails to the 3′ ends of the miRNAs, and
M-MLV RTase and a unique oligo-dT adaptor primer were
used to transcribe the poly(A)-tailed miRNAs to generate a
cDNA library. The All-in-One qPCR Mix containing SYBR
green I along with the miRNA-specific primers and the
general primer were used to produce the respective cDNAs
for all EBV-encoded miRNA species using an ABI7900HT
Fast Real-Time PCR System (Applied Biosystems, USA).
Thermal cycling was performed as follows: initial denatur-
ation at 95°C for 10 min; 40 cycles of denaturation at 95°C
for 10 s, annealing at 60°C for 20 s and extension at 72°Cfor 10 s; and a final extension at 72°C for 10 min (GeneCo-
poeia, USA). The specificity of the qPCR products was
evaluated and then verified by melting curve analysis, gel
electrophoresis and AT cloning-based DNA sequencing
(pMD18-T, TAKARA, Japan). The genomic locations of
the EBV miRNA genes are illustrated in Figure 1, and all of
the miRNA-specific forward primers that were used are
listed in Additional file 1: Table S2. The EBV-negative NPC
cell line CNE2 was used as a negative control, and the
housekeeping gene U6 was used as an internal control for
normalization. Each qPCR reaction was run in triplicate,
and the relative expression levels were calculated using the
comparative method (2-ΔΔCt) [34].
Microarray evaluation of human and viral miRNA expression
The oligonucleotide microarray for the analysis of micro-
RNAs was fabricated in-house, as described previously
with minor modifications [60]. Briefly, pre-cleaned, Gold
Seal slides (Thermo Fisher Scientific Inc.) were washed
with detergents and baked at 140°C for 4 hours, and then
the probes (40 nM final concentration) were mixed with
printing buffer at a 1:4 ratio and were printed onto the
slides at a constant temperature and humidity using a
SmartArrayer 136 printer (CapitalBio Inc., Beijing, China).
The microRNA probe set included human and EBV miR-
NAs that were registered in Sanger miRBase Release 12.0
(www.mirbase.org), and several positive and negative con-
trols were designed and labeled, in part, according to other
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are listed in Additional file 1: Table S2. The probe labeling
and hybridization were performed, in part, as described
previously with minor modifications [30,61]. Briefly, 2.5 μg
of total RNA was labeled with 2 nmol of pCp-DY647 or
pCp-DY547 (Dharmacon, USA) using 15 units of T4 RNA
ligase (GE Healthcare, USA) in a total reaction volume of
20 μL at 16°C overnight. The resulting 2.5 μg of labeled,
small RNA-enriched total RNA was purified using Bio-
Spin 6 desalting columns (BIO-RAD, USA) and then con-
densed in vacuum. These miRNAs were hybridized to pre-
treated chips in 1× hybridization solution (5× Denhardt’s
solution, 0.5% SDS, 5× SSC) in a hybridization chamber at
46°C for 24 hours, which was followed by slide washing
and scanning with a LuxScan™ 10 K Microarray Scanner
(CapitalBio Inc., China). Subsequently, the scanned images
were analyzed using GenPix Pro 6.0 (Axon Instruments, U.
S.A.), all data were MIAME compliant, and the raw data
have been deposited into a MIAME-compliant database
(GSE33225).Clustering analysis
Given the higher sensitivity, specificity and reliability
of qPCR analysis compared to microarray evaluation,
we performed unsupervised clustering analysis using
the normalized qPCR data [28,62]. The tumor cell lines
and tissues with different EBV latency types were
clustered using TMEV (TIGR multiarray experiment
viewer, version 4.2.01, http://www.tm4.org/) based on
the EBV miRNA expression levels that were quantified
by poly(A)-tailed, quantitative real-time RT-PCR, and
the data were log2 transformed. The hierarchical cluster-
ing of the EBV miRNA species and the classical typing
markers, including Cp, Wp and Qp activity and LMP1
expression, was performed using average linkage cluster-
ing, and the Euclidian distance matrix was calculated.Additional file
Additional file 1: Table S1. The PCR primers sequences for viral latent
genes. Table S2. The PCR primer and microarray probe sequences for
EBV miRNA species.
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